Studying the potential of upregulated PTGS2 and VEGF-C besides hyper-methylation of PTGS2 promoter as biomarkers of Acute myeloid leukemia.
DNA methylation
Gene expression
Leukemia, myeloid, acute
PTGS2 protein, human
Real-time polymerase chain reaction
Vascular endothelial growth factor C
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
12
06
2021
accepted:
18
05
2022
revised:
27
04
2022
pubmed:
23
6
2022
medline:
26
7
2022
entrez:
22
6
2022
Statut:
ppublish
Résumé
Hereby, we aimed to investigate the expression of prostaglandin-endoperoxide synthase 2 (PTGS2) and Vascular Endothelial Factor-C (VEGF-C) besides the methylation of PTGS2 in AML patients. VEGF-C and PTGS2 expression analysis were evaluated in newly diagnosed AML patients and healthy controls by quantitative Reverse Transcriptase PCR method. Also, PTGS2 methylation status was evaluated by Methylation-Sensitive High-Resolution Melting Curve Analysis (MS-HRM). While 34% of patients were female, the mean age of the patients was 43.41 ± 17.60 years suffering mostly from M4 (48.21%) type of AML. Although methylation level between patients and controls was not significantly different, none of the normal controls showed methylation in the PTGS2 promoter. PTGS2 and VEGF-C levels were elevated in AML cases and correlated with WBC, Platelet, and Hemoglobin levels. The survival of patients with overexpressed VEGF-C and PTGS2 was poorer than others. It can be concluded that PTGS2 and especially VEGF-C expression but not PTGS2 methylation can be considered as diagnostic biomarkers for AML.
Identifiants
pubmed: 35733068
doi: 10.1007/s11033-022-07615-7
pii: 10.1007/s11033-022-07615-7
doi:
Substances chimiques
Biomarkers
0
Vascular Endothelial Growth Factor C
0
Cyclooxygenase 2
EC 1.14.99.1
PTGS2 protein, human
EC 1.14.99.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7849-7862Subventions
Organisme : Iran University of Medical Sciences
ID : 9511264005
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374(23):2209–2221
pubmed: 27276561
pmcid: 4979995
doi: 10.1056/NEJMoa1516192
De Kouchkovsky I, Abdul-Hay M (2016) Acute myeloid leukemia: a comprehensive review and 2016 update. Blood cancer journal 6(7):e441
pubmed: 27367478
pmcid: 5030376
doi: 10.1038/bcj.2016.50
Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447
pubmed: 27895058
pmcid: 5291965
doi: 10.1182/blood-2016-08-733196
Deschler B, Lübbert M (2006) Acute myeloid leukemia: epidemiology and etiology. Cancer: Interdisciplinary International Journal of the American Cancer Society 107(9):2099–2107
doi: 10.1002/cncr.22233
Puumala SE, Ross JA, Aplenc R, Spector LG (2013) Epidemiology of childhood acute myeloid leukemia. Pediatr Blood Cancer 60(5):728–733
pubmed: 23303597
pmcid: 3664189
doi: 10.1002/pbc.24464
Candal FJ, Rafii S, Parker JT, Ades EW, Ferris B, Nachman RL, Kellar KL (1996) BMEC-1: a human bone marrow microvascular endothelial cell line with primary cell characteristics. Microvasc Res 52(3):221–234
pubmed: 8954864
doi: 10.1006/mvre.1996.0060
Wouters BJ, Delwel R (2016) Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood 127(1):42–52
pubmed: 26660432
doi: 10.1182/blood-2015-07-604512
Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau J-P, Chou W-C, Buckstein R, Cermak J (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30(21):2670
pubmed: 22689805
pmcid: 4874148
doi: 10.1200/JCO.2011.38.9429
Dombret H, Gardin C (2016) An update of current treatments for adult acute myeloid leukemia. Blood 127(1):53–61
pubmed: 26660429
pmcid: 4705610
doi: 10.1182/blood-2015-08-604520
Tallman MS, Gilliland DG, Rowe JM (2005) Drug therapy for acute myeloid leukemia. Blood 106(4):1154–1163
pubmed: 15870183
doi: 10.1182/blood-2005-01-0178
Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen I-M, Head DR, Appelbaum FR, Willman CL (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89(9):3323–3329
pubmed: 9129038
doi: 10.1182/blood.V89.9.3323
Burnett A, Wetzler M, Lowenberg B (2011) Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29(5):487–494
pubmed: 21220605
doi: 10.1200/JCO.2010.30.1820
Chaudry SF, Chevassut TJ (2017) Epigenetic guardian: a review of the DNA methyltransferase DNMT3A in acute myeloid leukaemia and clonal haematopoiesis. BioMed research international 2017
Antica M (2011) Acute Leukemia: The Scientist’s Perspective and Challenge. BoD–Books on Demand
Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358(18):1909–1918
pubmed: 18450602
doi: 10.1056/NEJMoa074306
Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3):353–364
pubmed: 8756718
doi: 10.1016/S0092-8674(00)80108-7
Otrock ZK, Mahfouz RA, Makarem JA, Shamseddine AI (2007) Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Molecules and Diseases 39(2):212–220
doi: 10.1016/j.bcmd.2007.04.001
Behrmann L, Wellbrock J, Fiedler W (2018) Acute myeloid leukemia and the bone marrow niche–take a closer look. Front Oncol 8:444
pubmed: 30370251
pmcid: 6195156
doi: 10.3389/fonc.2018.00444
Zhou H-S, Carter BZ, Andreeff M (2016) Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang. Cancer biology & medicine 13(2):248
doi: 10.20892/j.issn.2095-3941.2016.0023
Medyouf H (2017) The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications. Blood 129(12):1617–1626
pubmed: 28159735
doi: 10.1182/blood-2016-11-696070
Kampen KR, Ter Elst A, de Bont ES (2013) Vascular endothelial growth factor signaling in acute myeloid leukemia. Cell Mol Life Sci 70(8):1307–1317
pubmed: 22833169
doi: 10.1007/s00018-012-1085-3
de Jonge HJ, Valk PJ, Veeger NJ, ter Elst A, den Boer ML, Cloos J, de Haas V, van den Heuvel-Eibrink MM, Kaspers GJ, Zwaan CM (2010) High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood 116(10):1747–1754
pubmed: 20522712
doi: 10.1182/blood-2010-03-270991
Liersch R, Schliemann C, Bieker R, Hintelmann H, Buechner T, Berdel WE, Mesters RM (2008) Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia. Leuk Res 32(6):954–961
pubmed: 18006056
doi: 10.1016/j.leukres.2007.10.005
Lee C, Tien H-F, Hu C, Chou W, Lin L (2007) Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia. Br J Cancer 97(7):877
pubmed: 17848952
pmcid: 2360422
doi: 10.1038/sj.bjc.6603966
Jana S, Chatterjee K, Ray AK, DasMahapatra P, Swarnakar S (2016) Regulation of matrix metalloproteinase-2 activity by COX-2-PGE2-pAKT axis promotes angiogenesis in endometriosis. PLoS ONE 11(10):e0163540
pubmed: 27695098
pmcid: 5047632
doi: 10.1371/journal.pone.0163540
Akhtar M, Cheng Y, Magno RM, Ashktorab H, Smoot DT, Meltzer SJ, Wilson KT (2001) Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer Res 61(6):2399–2403
pubmed: 11289104
Kikuchi T, Itoh F, Toyota M, Suzuki H, Yamamoto H, Fujita M, Hosokawa M, Imai K (2002) Aberrant methylation and histone deacetylation of cyclooxygenase 2 in gastric cancer. Int J Cancer 97(3):272–277
pubmed: 11774276
doi: 10.1002/ijc.1612
Vosooghi M, Amini M (2014) The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies. Expert Opin Drug Discov 9(3):255–267
pubmed: 24483845
doi: 10.1517/17460441.2014.883377
Davila-Gonzalez D, Chang JC, Billiar TR (2017) NO and COX2: Dual targeting for aggressive cancers. Proceedings of the National Academy of Sciences 114 (52):13591–13593
Hou H-A, Chou W-C, Lin L-I, Tang J-L, Tseng M-H, Huang C-F, Yao M, Chen C-Y, Tsay W, Tien H-F (2008) Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk Res 32(6):904–912
pubmed: 17904634
doi: 10.1016/j.leukres.2007.08.010
Gately S, Li WW (2004) Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Seminars in Oncology. Elsevier, pp 2–11
Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M (2010) The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. International journal of cell biology 2010
Aliparasti MR, Almasi S, Sanaat Z, Movasaghpoor A, Khalili-Dizaji R, Sadeghi-Bazargani H (2013) Gene expression of VEGF-A and VEGF-C in peripheral blood mononuclear cells of iranian patients with acute myeloid leukemia. Turkish J Hematol 30(2):137
doi: 10.4274/Tjh.2011.0023
Rafii S, Shapiro F, Pettengell R, Ferris B, Nachman RL, Moore M, Asch A (1995) Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. Blood 86(9):3353–3363
pubmed: 7579438
doi: 10.1182/blood.V86.9.3353.bloodjournal8693353
Fiedler W, Graeven U, Ergün S, Verago S, Kilic N, Stockschläder M, Hossfeld DK (1997) Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 89(6):1870–1875
pubmed: 9058706
doi: 10.1182/blood.V89.6.1870
Deeb G, Vaughan MM, McInnis I, Ford LA, Sait SN, Starostik P, Wetzler M, Mashtare T, Wang ES (2011) Hypoxia-inducible factor-1α protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk Res 35(5):579–584
pubmed: 21176961
doi: 10.1016/j.leukres.2010.10.020
Dias S, Choy M, Alitalo K, Rafii S (2002) Vascular endothelial growth factor (VEGF)–C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 99(6):2179–2184
pubmed: 11877295
doi: 10.1182/blood.V99.6.2179
Chien M-H, Ku C-C, Johansson G, Chen M-W, Hsiao M, Su J-L, Inoue H, Hua K-T, Wei L-H, Kuo M-L (2009) Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. Carcinogenesis 30(12):2005–2013
pubmed: 19825968
doi: 10.1093/carcin/bgp244
Guo X, Chen Y, Xu Z, Xu Z, Qian Y, Yu X (2009) Prognostic significance of VEGF-C expression in correlation with COX-2, lymphatic microvessel density, and clinicopathologic characteristics in human non-small cell lung cancer. Acta Biochim Biophys Sin 41(3):217–222
pubmed: 19280060
doi: 10.1093/abbs/gmp004
Lilly MB, Drapiza L, Sheth M, Zemskova M, Bashkirova S, Morris J (2004) Expression of Cyclooxygenase-2 (COX-2) in Human Leukemias and Hematopoietic Cells. American Society of Hematology
Carter BZ, Mak PY, Wang X, Tao W, Ruvolo V, Mak D, Mu H, Burks JK, Andreeff M (2019) An ARC-Regulated IL1β/Cox-2/PGE2/β-Catenin/ARC Circuit Controls Leukemia–Microenvironment Interactions and Confers Drug Resistance in AML. Cancer Res 79(6):1165–1177
pubmed: 30674535
pmcid: 6420856
doi: 10.1158/0008-5472.CAN-18-0921
Muntean AG, Tan J, Sitwala K, Huang Y, Bronstein J, Connelly JA, Basrur V, Elenitoba-Johnson KS, Hess JL (2010) The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell 17(6):609–621. doi: https://doi.org/10.1016/j.ccr.2010.04.012
doi: 10.1016/j.ccr.2010.04.012
pubmed: 20541477
pmcid: 2888888
Kvinlaug BT, Chan WI, Bullinger L, Ramaswami M, Sears C, Foster D, Lazic SE, Okabe R, Benner A, Lee BH, De Silva I, Valk PJ, Delwel R, Armstrong SA, Dohner H, Gilliland DG, Huntly BJ (2011) Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer Res 71(12):4117–4129. doi: https://doi.org/10.1158/0008-5472.CAN-11-0176
doi: 10.1158/0008-5472.CAN-11-0176
pubmed: 21505102
pmcid: 3119437
Martin-Subero JI, Ammerpohl O, Bibikova M, Wickham-Garcia E, Agirre X, Alvarez S, Bruggemann M, Bug S, Calasanz MJ, Deckert M, Dreyling M, Du MQ, Durig J, Dyer MJ, Fan JB, Gesk S, Hansmann ML, Harder L, Hartmann S, Klapper W, Kuppers R, Montesinos-Rongen M, Nagel I, Pott C, Richter J, Roman-Gomez J, Seifert M, Stein H, Suela J, Trumper L, Vater I, Prosper F, Haferlach C, Cruz Cigudosa J, Siebert R (2009) A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS ONE 4(9):e6986. doi: https://doi.org/10.1371/journal.pone.0006986
doi: 10.1371/journal.pone.0006986
pubmed: 19750229
pmcid: 2737286
Stirewalt DL, Meshinchi S, Kopecky KJ, Fan W, Pogosova-Agadjanyan EL, Engel JH, Cronk MR, Dorcy KS, McQuary AR, Hockenbery D, Wood B, Heimfeld S, Radich JP (2008) Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer 47(1):8–20. doi: https://doi.org/10.1002/gcc.20500
doi: 10.1002/gcc.20500
pubmed: 17910043
Gebhard C, Schwarzfischer L, Pham TH, Schilling E, Klug M, Andreesen R, Rehli M (2006) Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. Cancer Res 66(12):6118–6128. doi: https://doi.org/10.1158/0008-5472.CAN-06-0376
doi: 10.1158/0008-5472.CAN-06-0376
pubmed: 16778185
Yagi T, Morimoto A, Eguchi M, Hibi S, Sako M, Ishii E, Mizutani S, Imashuku S, Ohki M, Ichikawa H (2003) Identification of a gene expression signature associated with pediatric AML prognosis. Blood 102(5):1849–1856. doi: https://doi.org/10.1182/blood-2003-02-0578
doi: 10.1182/blood-2003-02-0578
pubmed: 12738660
Gutierrez NC, Lopez-Perez R, Hernandez JM, Isidro I, Gonzalez B, Delgado M, Ferminan E, Garcia JL, Vazquez L, Gonzalez M, San Miguel JF (2005) Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia 19(3):402–409. doi: https://doi.org/10.1038/sj.leu.2403625
doi: 10.1038/sj.leu.2403625
pubmed: 15674361
Handschuh L, Kazmierczak M, Milewski MC, Goralski M, Luczak M, Wojtaszewska M, Uszczynska-Ratajczak B, Lewandowski K, Komarnicki M, Figlerowicz M (2018) Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR. Int J Oncol 52(3):656–678. doi: https://doi.org/10.3892/ijo.2017.4233
doi: 10.3892/ijo.2017.4233
pubmed: 29286103
Zhu YM, Wang PP, Huang JY, Chen YS, Chen B, Dai YJ, Yan H, Hu Y, Cheng WY, Ma TT, Chen SJ, Shen Y (2017) Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance. J Transl Med 15(1):178. doi: https://doi.org/10.1186/s12967-017-1279-4
doi: 10.1186/s12967-017-1279-4
pubmed: 28830460
pmcid: 5568401
Dawson MA, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150(1):12–27
pubmed: 22770212
doi: 10.1016/j.cell.2012.06.013
Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, van Putten W, Skrabanek L (2010) DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17(1):13–27
pubmed: 20060365
pmcid: 3008568
doi: 10.1016/j.ccr.2009.11.020
Claus R, Lübbert M (2003) Epigenetic targets in hematopoietic malignancies. Oncogene 22(42):6489
pubmed: 14528273
doi: 10.1038/sj.onc.1206814
Hackanson B, Bennett KL, Brena RM, Jiang J, Claus R, Chen S-S, Blagitko-Dorfs N, Maharry K, Whitman SP, Schmittgen TD (2008) Epigenetic modification of CCAAT/enhancer binding protein α expression in acute myeloid leukemia. Cancer Res 68(9):3142–3151
pubmed: 18451139
doi: 10.1158/0008-5472.CAN-08-0483
Karray-Chouayekh S, Trifa F, Khabir A, Boujelbene N, Sellami-Boudawara T, Daoud J, Frikha M, Gargouri A, Mokdad-Gargouri R (2011) Methylation status and overexpression of COX-2 in Tunisian patients with ductal invasive breast carcinoma. Tumor Biology 32(3):461–468
pubmed: 21153458
doi: 10.1007/s13277-010-0139-0
Yasuda H, Watanabe Y, Oikawa R, Itoh F (2018) Role of COX-2 Promoter Methylation and Helicobacter pylori Infection in Impaired Gastric Ulcer Healing
Pinheiro R, Harada ML, Rodriguez Burbano RM, Nascimento Borges Bd (2018) COX-2 gene expression and methylation profile in Sapajus apella as an experimental model for gastric adenocarcinoma. Genetics and molecular biology (AHEAD)
Igarashi K, Kawaguchi K, Li S, Han Q, Tan Y, Murakami T, Kiyuna T, Miyake K, Miyake M, Singh AS, Eckardt MA, Nelson SD, Russell TA, Dry SM, Li Y, Yamamoto N, Hayashi K, Kimura H, Miwa S, Tsuchiya H, Singh SR, Eilber FC, Hoffman RM (2018) Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma. Cancer Lett 417:168–173. doi: https://doi.org/10.1016/j.canlet.2017.12.028
doi: 10.1016/j.canlet.2017.12.028
pubmed: 29306021
Neureiter D, Jäger T, Ocker M, Kiesslich T (2014) Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. World J Gastroenterology: WJG 20(24):7830
pmcid: 4069312
doi: 10.3748/wjg.v20.i24.7830
Shafabakhsh R, Aghadavod E, Ghayour-Mobarhan M, Ferns G, Asemi Z (2019) Role of histone modification and DNA methylation in signaling pathways involved in diabetic retinopathy. J Cell Physiol 234(6):7839–7846
pubmed: 30515789
doi: 10.1002/jcp.27844
Dawsey SP, Roth MJ, Adams L, Hu N, Wang QH, Taylor PR, Woodson K (2008) COX-2 (PTGS2) gene methylation in epithelial, subepithelial lymphocyte and stromal tissue compartments in a spectrum of esophageal squamous neoplasia. Cancer Detect Prev 32(2):135–139. doi: https://doi.org/10.1016/j.cdp.2008.05.001
doi: 10.1016/j.cdp.2008.05.001
pubmed: 18632220
pmcid: 2629649
Chow L, Zhu L, Loo W, Lui E (2005) Aberrant methylation of cyclooxygenase-2 in breast cancer patients. Biomed Pharmacother 59:S264–S267
pubmed: 16507389
doi: 10.1016/S0753-3322(05)80042-3
de Maat MF, van de Velde CJ, Umetani N, de Heer P, Putter H, van Hoesel AQ, Meijer GA, van Grieken NC, Kuppen PJ, Bilchik AJ (2007) Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol 25(31):4887–4894
pubmed: 17971584
doi: 10.1200/JCO.2006.09.8921
Fang S, Chen S, Nurmi H, Leppanen VM, Jeltsch M, Scadden D, Silberstein L, Mikkola H, Alitalo K (2020) VEGF-C protects the integrity of the bone marrow perivascular niche in mice. Blood 136(16):1871–1883. doi: https://doi.org/10.1182/blood.2020005699
doi: 10.1182/blood.2020005699
pubmed: 32842144
pmcid: 7568034
Kampen KR, Scherpen FJG, Mahmud H, Ter Elst A, Mulder AB, Guryev V, Verhagen H, De Keersmaecker K, Smit L, Kornblau SM, De Bont E (2018) VEGFC Antibody Therapy Drives Differentiation of AML. Cancer Res 78(20):5940–5948. doi: https://doi.org/10.1158/0008-5472.CAN-18-0250
doi: 10.1158/0008-5472.CAN-18-0250
pubmed: 30185550
Yun JW, Bae YK, Cho SY, Koo H, Kim HJ, Nam DH, Kim SH, Chun S, Joo KM, Park WY (2019) Elucidation of Novel Therapeutic Targets for Acute Myeloid Leukemias with RUNX1-RUNX1T1 Fusion. Int J Mol Sci 20(7). doi: https://doi.org/10.3390/ijms20071717
Cancer Genome Atlas, Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, Hoadley K, Triche TJ Jr, Laird PW, Baty JD, Fulton LL, Fulton R, Heath SE, Kalicki-Veizer J, Kandoth C, Klco JM, Koboldt DC, Kanchi KL, Kulkarni S, Lamprecht TL, Larson DE, Lin L, Lu C, McLellan MD, McMichael JF, Payton J, Schmidt H, Spencer DH, Tomasson MH, Wallis JW, Wartman LD, Watson MA, Welch J, Wendl MC, Ally A, Balasundaram M, Birol I, Butterfield Y, Chiu R, Chu A, Chuah E, Chun HJ, Corbett R, Dhalla N, Guin R, He A, Hirst C, Hirst M, Holt RA, Jones S, Karsan A, Lee D, Li HI, Marra MA, Mayo M, Moore RA, Mungall K, Parker J, Pleasance E, Plettner P, Schein J, Stoll D, Swanson L, Tam A, Thiessen N, Varhol R, Wye N, Zhao Y, Gabriel S, Getz G, Sougnez C, Zou L, Leiserson MD, Vandin F, Wu HT, Applebaum F, Baylin SB, Akbani R, Broom BM, Chen K, Motter TC, Nguyen K, Weinstein JN, Zhang N, Ferguson ML, Adams C, Black A, Bowen J, Gastier-Foster J, Grossman T, Lichtenberg T, Wise L, Davidsen T, Demchok JA, Shaw KR, Sheth M, Sofia HJ, Yang L, Downing JR, Eley G (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368(22):2059–2074. doi: https://doi.org/10.1056/NEJMoa1301689
doi: 10.1056/NEJMoa1301689
Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d’Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DKt, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ (2018) Functional genomic landscape of acute myeloid leukaemia. Nature 562(7728):526–531. doi: https://doi.org/10.1038/s41586-018-0623-z
doi: 10.1038/s41586-018-0623-z
pubmed: 30333627
pmcid: 6280667
Hua K-T, Lee W-J, Yang S-F, Chen C-K, Hsiao M, Ku C-C, Wei L-H, Kuo M-L, Chien M-H (2014) Vascular endothelial growth factor-C modulates proliferation and chemoresistance in acute myeloid leukemic cells through an endothelin-1-dependent induction of cyclooxygenase-2. Biochim et Biophys Acta (BBA)-Molecular Cell Res 1843(2):387–397
doi: 10.1016/j.bbamcr.2013.10.015
Mitchell C, Johnson R, Bisits A, Hirst J, Zakar T (2011) PTGS2 (prostaglandin endoperoxide synthase-2) expression in term human amnion in vivo involves rapid mRNA turnover, polymerase-II 5’-pausing, and glucocorticoid transrepression. Endocrinology 152(5):2113–2122. doi: https://doi.org/10.1210/en.2010-1327
doi: 10.1210/en.2010-1327
pubmed: 21385935
Kang JY, Song SH, Yun J, Jeon MS, Kim HP, Han SW, Kim TY (2015) Disruption of CTCF/cohesin-mediated high-order chromatin structures by DNA methylation downregulates PTGS2 expression. Oncogene 34(45):5677–5684. doi: https://doi.org/10.1038/onc.2015.17
doi: 10.1038/onc.2015.17
pubmed: 25703332
da Luz CM, da Broi MG, Donabela FC, Paro de Paz CC, Meola J, Navarro PA (2017) PTGS2 down-regulation in cumulus cells of infertile women with endometriosis. Reprod Biomed Online 35(4):379–386. doi: https://doi.org/10.1016/j.rbmo.2017.06.021
doi: 10.1016/j.rbmo.2017.06.021
pubmed: 28734688
Jin Z, Ren J, Qi S (2020) Human bone mesenchymal stem cells-derived exosomes overexpressing microRNA-26a-5p alleviate osteoarthritis via down-regulation of PTGS2. Int Immunopharmacol 78:105946. doi: https://doi.org/10.1016/j.intimp.2019.105946
doi: 10.1016/j.intimp.2019.105946
pubmed: 31784400
Walker MR, Brown SL, Riehl TE, Stenson WF, Stappenbeck TS (2010) Growth factor regulation of prostaglandin-endoperoxide synthase 2 (Ptgs2) expression in colonic mesenchymal stem cells. J Biol Chem 285(7):5026–5039. doi: https://doi.org/10.1074/jbc.M109.032672
doi: 10.1074/jbc.M109.032672
pubmed: 20018844